10 Common 21 CFR Part 11 Compliance Gaps and How to Fix Them
Navigating FDA Title 21 CFR Part 11 compliance remains a high-stakes challenge for pharma, biotech, and medical device companies. Regulators continue to issue 483s and Warning Letters for data integrity and system control failures. Here are 10 prevalent Part 11 gaps and how to resolve them. 1. Unvalidated SaaS & [...]